Gut Microbiome Clinical Trial
Official title:
Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study
The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes in fungal populations in the gut microbiome.
The human gastrointestinal tract hosts a diverse microbial community that has a role in influencing the host's pathophysiological responses. Although there is an abundance of metagenomic data available, the functional dynamics of the gut microbiota still need exploration in different conditions. The microbiota produces various metabolites from dietary products, impacting both host health and pathophysiological functions. The metabolites produced by different microbiota may selectively suppress or stimulate the growth of some components of the gut microbiome, ultimately influencing the dynamic of gut bacterial and fungal populations. Our lab is specifically interested in a metabolite, known as phenylpropionic acid (PPA) produced by a human gut resident bacteria known as Clostridium sporogenes. C.sporogenes produces PPA by metabolizing the amino acid, L-phenylalanine, which is sourced from human diet. Many studies have observed the antimicrobial and antifungal effects of PPA. Our lab determined the antifungal activity of PPA through decreased levels of Candida albicans in the mouse gut. We are interested in investigating how diversity in mycobiota populations, which focuses on the fungi species in the human gut, are related to changes in PPA levels. Therefore, this study will assess whether additional oral supplementation of L-Phenylalanine has any effect on the way C. sporogenes metabolizes phenylalanine. Healthy subjects will receive a 14-day supply of L-phenylalanine supplements and will provide stool and blood samples to the study team. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05793112 -
INF108F in Infants With Food Protein Induced Proctocolitis
|
Phase 4 | |
| Active, not recruiting |
NCT04327141 -
Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women
|
N/A | |
| Recruiting |
NCT04117321 -
Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
|
||
| Recruiting |
NCT05655910 -
Enhanced Nutritional Optimization in LVAD Trial
|
N/A | |
| Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
| Active, not recruiting |
NCT05931471 -
Yogurt and GI Health
|
N/A | |
| Recruiting |
NCT03797417 -
Gut Microbiome and Metabolic Pathways Changes in Vitiligo
|
||
| Withdrawn |
NCT06006416 -
Effect of Fenugreek Fibre on Gut Microbiome
|
Phase 3 | |
| Recruiting |
NCT06206486 -
The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
|
||
| Completed |
NCT02655250 -
Neonatal Microbiome Validity Study
|
||
| Recruiting |
NCT05670288 -
Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
|
||
| Not yet recruiting |
NCT03975764 -
Fecal Microbiota in Preterm Birth
|
||
| Completed |
NCT03219931 -
NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants
|
Phase 4 | |
| Recruiting |
NCT04466072 -
Gut Microbiome and Ventricular Arrhythmias
|
||
| Recruiting |
NCT04447365 -
The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
|
||
| Not yet recruiting |
NCT06130137 -
Gut Microbiome in People Living With HIV and HBV
|
||
| Recruiting |
NCT06260579 -
Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity
|
N/A | |
| Completed |
NCT04511052 -
Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06424691 -
Infant Restore: Efficacy of Microbiome Analysis and Education
|
N/A | |
| Recruiting |
NCT06404749 -
Fungal Fiber for Gut Health
|
N/A |